Credit Suisse Maintains Neutral on PTC Therapeutics, Lowers Price Target to $50
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Judah Frommer maintains a Neutral rating on PTC Therapeutics (NASDAQ:PTCT) and lowers the price target from $55 to $50.
May 24, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Credit Suisse analyst Judah Frommer maintains a Neutral rating on PTC Therapeutics and lowers the price target from $55 to $50.
The news directly mentions PTC Therapeutics (PTCT) and the lowered price target by Credit Suisse. This may cause some investors to reconsider their positions, but the Neutral rating suggests that the stock's overall outlook remains unchanged. The short-term impact on the stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100